# TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

> **NCT05507541** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 10 (actual)

## Conditions studied

- Recurrent ALK Positive Large B-Cell Lymphoma
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Grade 3b Follicular Lymphoma
- Recurrent High Grade B-Cell Lymphoma
- Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Intravascular Large B-Cell Lymphoma
- Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Refractory ALK Positive Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory Grade 3b Follicular Lymphoma
- Refractory High Grade B-Cell Lymphoma
- Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified
- Refractory Intravascular Large B-Cell Lymphoma
- Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Recurrent Gray Zone Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Ontorpacept
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Maplirpacept
- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT05507541
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-19
- **Primary completion:** 2027-07-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05507541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05507541, "TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05507541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*